Construction and validation of a nomogram model to predict bronchiolitis Mycoplasma pneumoniae pneumonia in children

Shuping Xiong1,2, Lihua Lin3,1, Qihong Chen3,1

  • 1Department of Pediatrics, Pediatric Key Laboratory of Xiamen, the First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.

Scientific Reports
|December 27, 2024
PubMed

Insights

Pediatric bronchiolitis caused by Mycoplasma pneumoniae (MP) is increasing. Researchers developed a nomogram model using age, atopy, wheezing, hypoxemia, and pleural effusion to predict bronchiolitis Mycoplasma pneumoniae pneumonia (MPP) risk for early intervention.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Medical Diagnostics

Background:

  • Post-COVID-19, pediatric Mycoplasma pneumoniae (MP) infections, including bronchiolitis, have risen.
  • Some children develop residual bronchiolitis obliterans (BO) after MP infection.
  • Diagnosing bronchiolitis Mycoplasma pneumoniae pneumonia (MPP) typically relies on high-resolution computed tomography (HRCT).

Purpose of the Study:

  • To develop and validate a predictive model for bronchiolitis MPP.
  • To identify key clinical factors for predicting MPP risk.
  • To facilitate early and individualized intervention for affected children.

Main Methods:

  • Retrospective analysis of pediatric patients diagnosed with bronchiolitis MPP.
  • Random division into training and validation cohorts.
  • Construction of a nomogram model using logistic stepwise regression.

Main Results:

  • Age, atopy, wheezing, hypoxemia, and pleural effusion were identified as independent predictors of bronchiolitis MPP.
  • A nomogram model was successfully constructed and validated.
  • The model demonstrated good differential, calibration, and clinical applicability.

Conclusions:

  • The developed nomogram model is a valuable tool for predicting the risk of bronchiolitis MPP in children.
  • Early risk prediction can aid in timely and personalized treatment strategies.
  • Further research may refine predictive capabilities for pediatric respiratory infections.